Edition:
United States

AcelRx Pharmaceuticals Inc (ACRX.OQ)

ACRX.OQ on NASDAQ Stock Exchange Global Market

3.10USD
17 Feb 2017
Change (% chg)

-- (--)
Prev Close
$3.10
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
33,043
52-wk High
$4.36
52-wk Low
$2.41

ACRX.OQ

Chart for ACRX.OQ

About

AcelRx Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. Its lead product... (more)

Overall

Beta: 2.80
Market Cap(Mil.): $140.53
Shares Outstanding(Mil.): 45.33
Dividend: --
Yield (%): --

Financials

  ACRX.OQ Industry Sector
P/E (TTM): -- 47.00 29.32
EPS (TTM): -0.98 -- --
ROI: -41.11 -4.07 13.03
ROE: -203.62 4.71 14.17

BRIEF-Acelrx Pharmaceuticals appoints Vincent Angotti as CEO

* Acelrx Pharmaceuticals appoints Vincent J. Angotti chief executive officer

Feb 16 2017

BRIEF-Acelrx Pharma says amended loan and security deal with Hercules Tech II and Hercules Capital Inc

* Among other things, amendment extends interest-only period from October 1, 2016 to April 1, 2017 - SEC filing

Oct 03 2016

BRIEF-AcelRx Pharmaceuticals initiates late-stage study of its painkiller

* Initiates phase 3 study of Zalviso in patients with moderate-to-severe acute post-operative pain Source text for Eikon: Further company coverage:

Sep 27 2016

AcelRx's opioid painkiller succeeds in key study

AcelRx Pharmaceuticals Inc said its experimental opioid painkiller was well tolerated in post-operative patients, including those with organ impairment and the elderly, in a late-stage study.

Sep 15 2016

UPDATE-1-AcelRx's opioid painkiller succeeds in key study

Sept 15 AcelRx Pharmaceuticals Inc said its experimental opioid painkiller was well tolerated in post-operative patients, including those with organ impairment and the elderly, in a late-stage study.

Sep 15 2016

BRIEF-Acelrx reports positive results for ARX-04 in Phase 3 registration trial

* Reports positive results for ARX-04 (sufentanil sublingual tablet, 30 mcg), including in elderly patients and patients with organ impairment, in third Phase 3 registration trial, SAP303

Sep 15 2016

BRIEF-Acelrx Pharmaceuticals posts results from phase 3 study of ARX-04

* Acelrx pharmaceuticals presents results from phase 3 study of ARX-04 in the emergency department at the international society for burn injuries

Aug 29 2016

More From Around the Web

Earnings vs. Estimates